Acrivon Therapeutics (NASDAQ:ACRV) Stock Rating Upgraded by Wall Street Zen

Acrivon Therapeutics (NASDAQ:ACRV) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

A number of other equities analysts also recently weighed in on ACRV. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Acrivon Therapeutics in a research report on Monday, December 29th. Piper Sandler boosted their price objective on shares of Acrivon Therapeutics from $6.00 to $8.00 and gave the stock an “overweight” rating in a research report on Friday, January 9th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $19.00 target price on shares of Acrivon Therapeutics in a research report on Tuesday, November 25th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $11.67.

Acrivon Therapeutics Price Performance

Shares of Acrivon Therapeutics stock opened at $1.53 on Friday. The firm has a market cap of $48.29 million, a price-to-earnings ratio of -0.72 and a beta of 1.74. The stock’s 50-day moving average is $2.01 and its 200-day moving average is $1.89. Acrivon Therapeutics has a one year low of $1.05 and a one year high of $5.96.

Insider Buying and Selling

In other Acrivon Therapeutics news, CEO Peter Blume-Jensen purchased 49,000 shares of Acrivon Therapeutics stock in a transaction that occurred on Wednesday, January 14th. The stock was acquired at an average price of $1.68 per share, for a total transaction of $82,320.00. Following the completion of the acquisition, the chief executive officer owned 2,095,771 shares of the company’s stock, valued at approximately $3,520,895.28. This trade represents a 2.39% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Insiders bought a total of 67,832 shares of company stock worth $114,534 in the last three months. Company insiders own 11.90% of the company’s stock.

Institutional Trading of Acrivon Therapeutics

A number of hedge funds have recently made changes to their positions in ACRV. UBS Group AG boosted its stake in shares of Acrivon Therapeutics by 150,057.8% during the 3rd quarter. UBS Group AG now owns 683,218 shares of the company’s stock worth $1,237,000 after acquiring an additional 682,763 shares during the period. Renaissance Technologies LLC lifted its holdings in Acrivon Therapeutics by 1.7% during the 4th quarter. Renaissance Technologies LLC now owns 634,169 shares of the company’s stock valued at $1,528,000 after purchasing an additional 10,769 shares during the last quarter. Marshall Wace LLP boosted its position in Acrivon Therapeutics by 231.4% during the fourth quarter. Marshall Wace LLP now owns 496,081 shares of the company’s stock worth $1,196,000 after purchasing an additional 346,366 shares during the period. Jane Street Group LLC increased its holdings in shares of Acrivon Therapeutics by 18.3% in the fourth quarter. Jane Street Group LLC now owns 342,071 shares of the company’s stock valued at $824,000 after purchasing an additional 52,823 shares during the last quarter. Finally, Two Sigma Investments LP increased its holdings in shares of Acrivon Therapeutics by 76.2% in the third quarter. Two Sigma Investments LP now owns 319,205 shares of the company’s stock valued at $578,000 after purchasing an additional 138,033 shares during the last quarter. 71.62% of the stock is owned by institutional investors and hedge funds.

About Acrivon Therapeutics

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.